At a glance
- Originator Merck & Co
- Class Antiacnes
- Mechanism of Action Cholestenone 5-alpha reductase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Acne
Most Recent Events
- 10 Nov 2000 No-Development-Reported for Acne in USA (Unknown route)
- 20 Feb 1997 New profile
- 20 Feb 1997 Preclinical development for Acne in USA (Unknown route)